Oncotarget

Research Papers:

Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer

Yanyun Zhu, Wen Si, Qiong Sun, Boyu Qin, Weihong Zhao and Junlan Yang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:1023-1030. https://doi.org/10.18632/oncotarget.13714

Metrics: PDF 2592 views  |   HTML 2443 views  |   ?  


Abstract

Yanyun Zhu1,*, Wen Si2,*, Qiong Sun1, Boyu Qin1, Weihong Zhao1, Junlan Yang1

1Department of Medical Oncology, Chinese PLA General Hospital, Beijing 100853, China

2Department of Medical Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China

*These authors contributed equally to this work

Correspondence to:

Weihong Zhao, email: [email protected]

Junlan Yang, email: [email protected]

Keywords: breast cancer, prognosis, biomarker, meta-analysis, PLR

Received: August 23, 2016     Accepted: November 16, 2016     Published: November 30, 2016

ABSTRACT

Platelet-lymphocyte ratio (PLR) is a hematological parameter which is investigated as a biomarker for prognosis in patients with breast cancer. Due to the controversial results from previous studies, we performed a meta-analysis. Databases of PubMed, Embase and Web of Science were searched to identify eligible studies. STATA version 12.0 was used for statistical analysis. Seven studies with 3,741 patients were ultimately included in this meta-analysis. High PLR was associated with poor overall survival (OS) (HR = 1.55, 95% CI = 1.07–2.25, p = 0.022) and disease-free survival (DFS) (HR = 1.73, 95% CI = 1.3-2.3, p < 0.001) in breast cancer patients. Subgroup analyses disclosed that elevated PLR could predict worse OS in Asian populations and poor DFS in both Asian and non-Asian patients. In addition, PLR remains a significant prognostic marker for OS in patients receiving systemic treatment (HR = 1.78, 95% CI = 1.06–2.99, p = 0.03) and patients receiving chemotherapy (HR = 2.82, 95% CI = 1.09–7.26, p = 0.032). High PLR also indicates poor DFS in patients who receive chemotherapy (HR = 2.6, 95% CI = 1.47–4.61, p = 0.001), surgery (HR = 1.8, 95% CI = 1.12–2.89, p = 0.016) and systemic treatment (HR = 2.03, 95% CI = 1.03–4.01, p = 0.042). Moreover, PLR was also in association with HER-2 positivity (OR = 1.48, 95% CI = 1.2–1.83, p < 0.001). In conclusion, this meta-analysis revealed that PLR could serve as an indicator of poor prognosis in patients with breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13714